Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups
Top Cited Papers
Open Access
- 6 May 2010
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 115 (18) , 3827-3834
- https://doi.org/10.1182/blood-2009-12-255992
Abstract
Warfarin-dosing algorithms incorporating CYP2C9 and VKORC1 −1639G>A improve dose prediction compared with algorithms based solely on clinical and demographic factors. However, these algorithms better capture dose variability among whites than Asians or blacks. Herein, we evaluate whether other VKORC1 polymorphisms and haplotypes explain additional variation in warfarin dose beyond that explained by VKORC1 −1639G>A among Asians (n = 1103), blacks (n = 670), and whites (n = 3113). Participants were recruited from 11 countries as part of the International Warfarin Pharmacogenetics Consortium effort. Evaluation of the effects of individual VKORC1 single nucleotide polymorphisms (SNPs) and haplotypes on warfarin dose used both univariate and multi variable linear regression. VKORC1 −1639G>A and 1173C>T individually explained the greatest variance in dose in all 3 racial groups. Incorporation of additional VKORC1 SNPs or haplotypes did not further improve dose prediction. VKORC1 explained greater variability in dose among whites than blacks and Asians. Differences in the percentage of variance in dose explained by VKORC1 across race were largely accounted for by the frequency of the −1639A (or 1173T) allele. Thus, clinicians should recognize that, although at a population level, the contribution of VKORC1 toward dose requirements is higher in whites than in nonwhites; genotype predicts similar dose requirements across racial groups.Keywords
This publication has 50 references indexed in Scilit:
- Reconstructing Indian population historyNature, 2009
- Warfarin pharmacogenomics.2009
- A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin DosePLoS Genetics, 2009
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataNew England Journal of Medicine, 2009
- The largest prospective warfarin-treated cohort supports genetic forecastingBlood, 2009
- VKORC1 Polymorphisms, Haplotypes and Haplotype Groups on Warfarin Dose Among African–Americans and European–AmericansPharmacogenomics, 2008
- Prevalence in the United States of Selected Candidate Gene Variants: Third National Health and Nutrition Examination Survey, 1991-1994American Journal of Epidemiology, 2008
- African Genetic Diversity: Implications for Human Demographic History, Modern Human Origins, and Complex Disease MappingAnnual Review of Genomics and Human Genetics, 2008
- A genome-wide scan for common genetic variants with a large influence on warfarin maintenance doseBlood, 2008
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinClinical Pharmacology & Therapeutics, 2008